Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
出版年份 2017 全文链接
标题
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
作者
关键词
-
出版物
Blood Cancer Journal
Volume 7, Issue 3, Pages e549-e549
出版商
Springer Nature
发表日期
2017-03-31
DOI
10.1038/bcj.2017.27
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
- (2016) C. Pawlyn et al. CLINICAL CANCER RESEARCH
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation
- (2015) Zheng Zhou et al. LEUKEMIA & LYMPHOMA
- EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
- (2015) H. Hernando et al. MOLECULAR CANCER THERAPEUTICS
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- Curing myeloma at last: defining criteria and providing the evidence
- (2014) B. Barlogie et al. BLOOD
- Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
- (2014) B. Xu et al. BLOOD
- EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation
- (2014) William D. Bradley et al. CHEMISTRY & BIOLOGY
- Inhibiting Enhancer of Zeste Homolog 2 Promotes Cellular Senescence in Gastric Cancer Cells SGC-7901 by Activation of p21 and p16
- (2014) Jie Bai et al. DNA AND CELL BIOLOGY
- The H3K27me3 demethylase UTX in normal development and disease
- (2014) Joni Van der Meulen et al. Epigenetics
- A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
- (2014) Eileen M. Boyle et al. GENES CHROMOSOMES & CANCER
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Prognostic Value of Polycomb Proteins EZH2, BMI1 and SUZ12 and Histone Modification H3K27me3 in Colorectal Cancer
- (2014) Anne Benard et al. PLoS One
- Aberrant promoter methylation of p15 INK4b and p16 INK4a genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis
- (2014) Xuan Wang et al. TUMOR BIOLOGY
- Current and potential epigenetic targets in multiple myeloma
- (2014) Charlotte Pawlyn et al. Epigenomics
- Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma
- (2014) Jun Li et al. Drug Design Development and Therapy
- Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation
- (2014) Relja Popovic et al. PLoS Genetics
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
- (2013) Z. Huang et al. CANCER RESEARCH
- Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
- (2013) G. J. Morgan et al. CLINICAL CANCER RESEARCH
- A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR
- (2013) M F Kaiser et al. LEUKEMIA
- EZH2 in normal and malignant hematopoiesis
- (2013) K Lund et al. LEUKEMIA
- Transcriptional regulation by Polycomb group proteins
- (2013) Luciano Di Croce et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- MMSET is the key molecular target in t(4;14) myeloma
- (2013) F Mirabella et al. Blood Cancer Journal
- Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
- (2012) G. J. Morgan et al. BLOOD
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
- (2011) K. D. Boyd et al. CLINICAL CANCER RESEARCH
- Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
- (2011) G. J. Morgan et al. HAEMATOLOGICA
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
- (2011) K D Boyd et al. LEUKEMIA
- EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression
- (2011) T. Fan et al. MOLECULAR CANCER RESEARCH
- NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
- (2011) Alex J. Kuo et al. MOLECULAR CELL
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
- (2010) F. van Rhee et al. BLOOD
- Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
- (2010) B. A. Walker et al. BLOOD
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- (2010) D. Hose et al. HAEMATOLOGICA
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Polycomb Target Genes Are Silenced in Multiple Myeloma
- (2010) Antonia Kalushkova et al. PLoS One
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
- (2009) Gijs van Haaften et al. NATURE GENETICS
- MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
- (2008) J. L.R. Brito et al. HAEMATOLOGICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started